MyOR

MYOR combines artificial intelligence and noninvasive monitoring of various biomarkers, including microbiome analytics, metabolites, biophysical properties, optical properties, and volatiles, to establish a comprehensive understanding of a person's health situation. This analysis enables the company to personalize interventions that can prevent or manage a variety of conditions and diseases. MYOR currently has three product lines: Precision Infant Care predicts the risk of atopic dermatitis from birth; Personalized Diabetic Foods monitors advanced glycation end products (AGE) and provides proprietary diabetic food products to decrease diabetic complications; and Personalized Pediatric Nutrition monitors iron levels in infants and toddlers and provides a personalized infant formula or iron supplement to support healthy development. All of the company's products are close to commercialization and offer innovative solutions for atopic dermatitis, diabetes, and iron deficiency. Additional products in development are designed for rapid microbiome profiling and presymptomatic diagnosis of depression.

40.8
40.8
NaN
NaN
NaN
NaN
Links
Valuation
$
Funding
$ 0.50 M
$ 0.50 M
Statistics
NA

MyOR

MYOR combines artificial intelligence and noninvasive monitoring of various biomarkers, including microbiome analytics, metabolites, biophysical properties, optical properties, and volatiles, to establish a comprehensive understanding of a person's health situation. This analysis enables the company to personalize interventions that can prevent or manage a variety of conditions and diseases. MYOR currently has three product lines: Precision Infant Care predicts the risk of atopic dermatitis from birth; Personalized Diabetic Foods monitors advanced glycation end products (AGE) and provides proprietary diabetic food products to decrease diabetic complications; and Personalized Pediatric Nutrition monitors iron levels in infants and toddlers and provides a personalized infant formula or iron supplement to support healthy development. All of the company's products are close to commercialization and offer innovative solutions for atopic dermatitis, diabetes, and iron deficiency. Additional products in development are designed for rapid microbiome profiling and presymptomatic diagnosis of depression.

General Information
Merck KGaAMerck KGaAMerck KGaAMerck KGaAMerck KGaA 
View All
0and0